Shifting Goals of Therapy in AYA ALL: From Transplant to Long-Term Remission with Pediatric-Inspired Regimens and Immunotherapy

Dr. Silverman asks Dr. Curran to address how frontline therapy goals have evolved for young adults with ALL in the era of pediatric-inspired regimens (PIRs). Dr. Curran describes a significant paradigm shift: the historical standard in adult oncology held that young, fit patients should achieve remission as a bridge to allogeneic stem cell transplant (allo-SCT), which was considered to offer the best chance of long-term cure. Data supporting PIRs in AYA ALL have fundamentally changed this calculus. For patients who achieve measurable residual disease (MRD) negativity after induction or consolidation on a PIR, outcomes are superior with continued chemotherapy compared to transition to allo-SCT. Dr. Curran now counsels newly diagnosed AYA patients that the goal is long-term remission with chemotherapy, reserving transplant discussions for those with persistent or recurrent disease. She notes that blinatumomab has further complicated the transplant decision by offering effective MRD clearance in patients with low-level residual disease, making the risk-benefit calculation for allo-SCT even less favorable in many cases.

Dr. Silverman reflects on how immunotherapy has transformed B-cell ALL (B-ALL) specifically. Early in his career, the primary concern at relapse was whether salvage therapy could achieve a second remission adequate to bridge a patient to transplant, driving upfront transplant decisions for the highest-risk patients. The availability of blinatumomab, CAR-T cell therapy, and inotuzumab ozogamicin has dramatically improved second-line outcomes, reducing transplant urgency in first remission. These agents are now moving into the frontline setting, with blinatumomab added to PIRs in AYA ALL based on extrapolation from the E1910 trial and pediatric data demonstrating improved event-free survival and reduced relapse risk. Dr. Curran confirms that the majority of adult AYA programs are now incorporating blinatumomab into PIR backbones, with CALGB 10403 outcomes already representing a major improvement over historic adult controls but still lagging behind pediatric ALL survival curves.

Dr. Silverman contextualizes this gap as partly biological: pediatric ALL has a higher proportion of favorable-risk subtypes that respond readily to treatment, whereas AYA and adult ALL populations carry a higher burden of adverse-risk disease. Medication adherence to oral chemotherapy components of PIRs is an additional factor, with pediatric data demonstrating inferior outcomes in non-adherent patients and a plausible but understudied role in AYA outcomes. He expresses optimism that immunotherapy agents may help overcome biologic risk differences, potentially producing comparable efficacy across favorable and high-risk disease subsets as combination PIR plus immunotherapy data mature.